We initially examined the effect of anti-EGFR mAbs Cetuximab (C), panitumumab (P) and checkpoint inhibitors nivolumab (N), pembrolizumab (PE), ipilimumab (IPI) on the autophagy and EGFR induction on colorectal cancer cell lines bearing BRAFV600E (RKO and Colo-205), in order to have an initial indication on the potential regulation of autophagy by these agents. Here, EGFR is linked to colorectal cancer.